---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-013783"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:20:32.429589+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Avalo acquires AVTX-009 anti-IL-1β mAb, closes $115.6M private placement; 2023 net loss $31.5M

## Summary
- Acquired AVTX-009 (anti-IL-1β mAb) via acquisition of AlmataBio for $15M in stock plus $7.5M at close; milestones up to $20M.
- Closed private placement for up to $185M, initial $115.6M upfront; cash runway into 2027.
- 2023 net loss $31.5M ($114 per share); cash $7.4M at Dec 31, 2023.
- Plans Phase 2 trial in hidradenitis suppurativa; topline data expected in 2026.
- Warrants issued at $5.80 per share; as-converted shares ~23.4M after transactions.

## SEC filing metadata
- accession: 0001628280-24-013783
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013783/0001628280-24-013783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013783/avtx-20240329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-013783
- JSON: https://secwatch.observer/filing/0001628280-24-013783.json
- Plain text: https://secwatch.observer/filing/0001628280-24-013783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.